USPTO serial 88377819
MIQURE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 1, 2021
- Examiner
- PARADEWELAI, BENJI YUEN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with MIQURE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $797*
Plus Government fees of $975
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Julianne Abelman
Julianne Abelman ABELMAN LAW PLLC16 Sutton Place, Suite 5BNew York, NY 10022United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicinal preparations for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases, namely, viral systems, gene therapy systems, nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors; Viral systems, gene therapy systems, nucleic acid delivery systems for medical purposes, namely, medicines for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; Pharmaceutical preparations and substances for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, vaccines, prophylaxis medicines and other pharmaceutical preparations all for use in nucleic acid-based therapy, gene therapy and cell therapy for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases | ACTIVE | — |
| 042 | Research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; Research and product development in the field of pharmaceutics | ACTIVE | — |
| 044 | Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; Consultancy in the field of pharmaceutics | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by uniQure IP B.V.
- Other trademarks owned by uniQure IP B.V.
- Other trademarks owned by uniQure IP B.V.
- Other trademarks owned by UNIQURE BIOPHARMA B.V.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MIQURE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 1, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jun 11, 2025 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jun 4, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jun 4, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 4, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jun 4, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 4, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 4, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 4, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2023 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| May 26, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| May 26, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 1, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 16, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 16, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 24, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 8, 2021 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Feb 5, 2021 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Feb 2, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 2, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 2, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 2, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 2, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 28, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jun 11, 2020 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Dec 5, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 5, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 5, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 4, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 4, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 4, 2019 | ALIE | ASSIGNED TO LIE | — |
| Nov 25, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 24, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 19, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 25, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 12, 2019 | NWAP | NEW APPLICATION ENTERED | — |